C12N 2760/18771
Demonstrated in vivo effect
C12N2760/18771 (Demonstrated in vivo effect) appears on 9 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 11
- Assignees
- 8
- Inventors
- 12
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 1 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 2 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof25 Jun 2024US 12,018,051 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof28 Feb 2023US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Parainfluenza virus 5 based vaccines3 Jan 2023US 11,542,527 B2University of Georgia Research Foundation, Inc.
- Parainfluenza virus 5 based vaccines25 Aug 2020US 10,752,916 B2University of Georgia Research Foundation, Inc.
- Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/piv3 f protein and uses thereof19 Sep 2024US 2024/0309053 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Recombinant human/bovine parainfluenza virus 1 (hpiv1) expressing a chimeric rsv/hpiv1 f protein and uses thereof14 Sep 2023US 2023/0287055 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Parainfluenza virus 5 based vaccines3 Dec 2020US 2020/0377908 A1University of Georgia Research Foundation, Inc.
- Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof3 Sep 2020US 2020/0277338 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Piv5 as an oncolytic agent19 Sep 2019US 2019/0284578 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof2US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2023
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof1US 10,654,898 B2The United States of America, as represented by the Secretary, Department of Health and Human Serices · 2020
- Parainfluenza virus 5 based vaccines1US 10,752,916 B2University of Georgia Research Foundation, Inc. · 2020
- Parainfluenza virus 5 based vaccines1US 9,505,807 B2University of Georgia Research Foundation, Inc. · 2016